# US 2001/0026923 A1 · Noninvasive detection of colorectal cancer and other gastrointestinal pathology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026923 A1
- Document ID: US20010026923A1
- Status: Published application
- Kind: A1
- Application number: 09/755,232
- Filed: 2001-01-08
- Published: 2001-10-04
- Earliest claimed: 1999-04-15
- Inventors: Padmanabhan P. Nair
- Web page: https://patentgrep.com/patent/US20010026923A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/40: against enzymes
- C12N 5/0679: {Cells of the gastro-intestinal tract}
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- C07K 2317/52: Constant or Fc region; Isotype
- G01N 2333/90241: acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
- G01N 2800/06: Gastro-intestinal diseases
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for isolating viable, biologically substantially pure exfoliated fecal colonocytes at normal ambient temperature is described. Immunocoprocytes and inflammatory cells indicative of certain gastrointestinal conditions and a noninvasive method for detecting colorectal cancer are set forth. Composition of transport and suspension media for isolation of colonocytes are detailed.

## Claims

### Claim 1

Viable, biologically substantially pure exfoliated fecal colonocytes isolated at normal ambient temperature.

### Claim 2 (depends on 1)

The colonocytes of claim 1 bearing marker indicative of specific gastrointestinal condition.

### Claim 3 (depends on 2)

The colonocytes of claim 2 bearing marker indicative of neoplastic transformation.

### Claim 4 (depends on 2)

The colonocytes of claim 2 bearing marker indicative of immune dysfunction.

### Claim 5 (depends on 2)

The colonocytes of claim 2 showing abnormality indicative of non-neoplastic gastrointestinal pathology.

### Claim 6 (depends on 1)

The colonocytes of claim 1 being epithelial or nonepithelial cells of lymphoid origin.

### Claim 7 (depends on 1)

The colonocytes of claim 1 expressing a chimeric immunoglobulin IgC.

### Claim 8 (depends on 1)

The colonocytes of claim 1 expressing only IgA and CFc.

### Claim 9 (depends on 1)

The colonocytes of claim 1 expressing only CFc.

### Claim 10

A transport medium for collecting a fecal sample, comprising:
(a) a sufficient amount of an agent to sequester proteases present in fecal matter;
(b) a sufficient amount of a mucolytic agent to destroy mucus present in fecal matter; and
(c) a sufficient amount of a bacteriocidal agent to inhibit bacterial activity in fecal matter.

### Claim 11 (depends on 10)

The transport medium of claim 10, wherein said agent for sequestering proteases is selected from the group consisting of plasma proteins, gel forming polymers and synthetic resins.

### Claim 12 (depends on 11)

The transport medium of claim 11. wherein said plasma proteins are bovine serum albumin, egg albumin or human serum albumin.

### Claim 13 (depends on 12)

The transport medium of claim 12, wherein the mucolytic agent is selected from the group consisting of N-acetyl cysteine, b-mercaptoethanol, capsaicin, dithiothreitol and guaiacol.

### Claim 14 (depends on 13)

The transport medium of claim 13, wherein the bacteriocidal agent is selected from the group consisting of thimerosal, antibiotics and sodium azide.

### Claim 15 (depends on 14)

The transport medium of claim 14 being a solution, comprising: 4 sodium bicarbonate 350-500 mg; bovine serum albumin 2.5-15 gm; N-acetyl cysteine 250-500 mg; Thimerosal 100-300 mg; and Puck's Saline G 500 ml.

### Claim 16 (depends on 15)

The transport medium of claim 15 being devoid of thimerosal, thereby transforming into a dispersion or suspension medium.

### Claim 17

A method for isolating biologically substantially pure exfoliated fecal colonocytes at normal ambient temperature, comprising the steps of:
(a) collecting a fecal sample in a transport medium maintained at normal ambient temperature;
(b) dispersing the fecal sample in said transport medium diluted with a suspension medium;
(c) sedimenting cells present in the diluted transport medium of step (b) to isolate the cells from impurities by layering the cell suspension over a medium of heavier density;
(d) subjecting the cells in step (c) to an influence resulting in the formation of a cellular band at a boundary with said heavier medium; then (e) recovering biologically substantially pure colonocytes from said cellular band.

### Claim 18 (depends on 17)

The method of claim 17, wherein said heavier medium is of density ranging from about 1.033 to 1.20.

### Claim 19 (depends on 18)

The method of claim 18, wherein said heavier medium is of density 1.20.

### Claim 20

A method for detecting colorectal cancer, comprising the steps of:
(a) obtaining biologically substantially pure colonocytes; then
(b) reacting said colonocytes with a reagent to detect the presence of a marker determinative of cancer, occurrence of a positive reaction of said colonocytes with said reagent being indicative of the presence of cancer.

### Claim 21 (depends on 20)

The method of claim 20, wherein said reagent is fluorescently labelled antibodies or plant lectins that generate a colored product.

### Claim 22

A method for determining mucosal immunity of GI tract, comprising the step of comparing the number of immunocoprocytes recovered from a subject whose GI tract mucosal immunity is to be determined, with the number of immunocoprocytes recovered from a normal subject, a statistically significant deviation from normal value being indicative of the level of immune dysfunction.

### Claim 23

A method for diagnosing GI tract pathology, comprising the step of determining the presence of inflammatory cells in a stool sample of a subject suspected of GI tract pathology, the presence of inflammatory cells being indicative of GI tract pathology.

### Claim 24 (depends on 23)

The method of claim 23, wherein the presence of inflammatory cells is determined by reacting the cells with antibodies to CD45 or COX-2, the cells that bind with said antibodies being inflammatory cells.

### Claim 25

A method of producing antigen-specific monoclonal antibodies, comprising the step of employing antigen-specific immunocoprocytes as a clone in a standard hybridoma technique and recovering antigen-specific monoclonal antibodies.
